Data to be Presented on the Company’s GEO-CM04S1 and Gedeptin Programs
ATLANTA, GA - April 15, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that members of its senior management team and other scientific representatives will participate in two upcoming industry events during April. Event details are as follows:
| World Vaccine Congress, April 22-24, 2025, Washington, DC | |
| Date/Time: | April 24, 2025 at 10:25 a.m. EDT (Room 207A) |
| Session Title: | Phase 2b Study Results That Evaluated and Compared GeoVax’s Multi-Antigen, Vaccine Candidate (GEO-CM04S1) to an Approved Vaccine Against COVID-19 |
| Speaker: | Don J. Diamond, PhD, Director, Division of Vaccine Research & Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center |
|
For more information on the conference, please visit |
|
| American Association of Cancer Research, April 25-30, 2025, Chicago, IL | |
| Date/Time: | April 29, 2025 from 9:00 a.m. to 12:00 p.m. CDT |
| Session Title: | Viral-Vectored, Gene-Directed Prodrug Therapy (Gedeptin) in Needle-Accessible Solid Tumors |
| Speaker: | J. Marc Pipas, MD, Executive Medical Director, Oncology |
|
For more information on the conference, please visit |
|
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. The Company is also developing GEO-MVA, a vaccine targeting Mpox and smallpox. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.
Company Contact:
info@geovax.com
678-384-7220
Investor Relations Contact:
geovax@precisionaq.com
212-698-8696
View the original release on www.newmediawire.com
